Sun Pharma faces halt order on eye-drop production at Assam plant
FROM THE WIRE · LIVEMINT.COM
Drug regulators flag failures in quality management system; Sun Pharmaceutical’s compliance report under review
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bearishA regulatory production halt can affect revenue and reputation of a major pharmaceutical producer.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Drug regulators flagged failures in Sun Pharmaceutical's quality management system.
- 02Sun Pharmaceutical's compliance report is under review.
- 03The recall concerns ophthalmic products, with eye-drop production to be halted at the Assam plant.